期刊文献+

分子分型在乳腺癌放疗中的价值及应用 被引量:3

Application of Molecular Subtype in Radiotherapy of Breast Cancer
原文传递
导出
摘要 乳腺癌作为高度分子异质性疾病,根据雌、孕激素受体及Her-2的表达可分为4型。研究显示不同的分型具有明显不同的临床特征,根据分子分型指导患者接受化疗、内分泌治疗或靶向治疗。随着对其研究的深入,越来越多的报道显示分子分型可以指导乳腺癌的放疗。 As a highly heterogeneous disease,according to the progesterone receptor (PR),estrogen receptor (ER) and the expression of Her-2, breast cancer can be classified into four types. Numerous researches show that different types have its distinct clinical features ,and molecular classification may provide guidance for precise treatment in chemotherapy,endocrine therapy or targeted therapy. Recent studies show that the molecular typing of breast cancer can also be applied into radiotherapy. This article will review the latest advances in this domain.
出处 《肿瘤学杂志》 CAS 2017年第3期170-174,共5页 Journal of Chinese Oncology
基金 国家自然科学基金(81372407)
关键词 乳腺肿瘤 分子分型 放射疗法 breast cancer molecular subtype radiotherapy
  • 相关文献

参考文献2

二级参考文献14

  • 1Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies- improving the management of early breast cancer: St Gallen Inter- national Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [ J]. Ann Oncol,2015, pii: mdv221.
  • 2Gangi A, Chung A, Mirocha J,et ak Breast-conserving therapy for triple-negative breast cancer[ J]. JAMA Surg,2014,149 ( 3 ) :252- 258.
  • 3Pilewskie M, Ho A, Orell E, et al. Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy [ J ]. Ann Surg Oncol, 2014,21 ( 4 ) : 1209-1214.
  • 4Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of dis- eordance between triple-receptor measurements in primary and re- current breast cancer[ J]. Ann Onco1,2009,20(12) :1953-1958.
  • 5Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diag- nosis of oestrogen receptor-positive breast cancer: ATLAS, a ran- domised trial[ J]. Lancet ,2013,381 (9869) :805-816.
  • 6Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer Version 2.2015[J]. J Natl Compr Cane Netw,2015,13(4) :448- 475.
  • 7Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubiein and cyclo- phosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 [ J]. J Clin Oneol,2005,23 (31) :7811-7819.
  • 8Piceart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastu- zumab after adjuvant chemotherapy in HER2-positive breast cancer [ J]. N Engl J Med,2005,353 (16) : 1659-1672.
  • 9Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in YiER2-positive breast cancer[ J ]. N Engl J Med,2011,365 ( 14 ) : 1273-1283.
  • 10Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[ J ]. J Clin Onco1,2008,26 ( 8 ) : 1275-1281.

共引文献1175

同被引文献23

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部